Four Regulatory Requirements, One Validation System (QMSR, MDR and RDC 751)

ISO 13485. FDA QMSR. MDR 745/2017. RDC 751/2022. An exporting manufacturer must answer to all of them. Here is the trap: treating each framework as a separate project - one dossier for ANVISA, another for the FDA and another for Europe - multiplies costs, creates internal contradictions and, ironically, weakens the case in every audit. The opposite approach works: one validation system, interpreted through several regulatory frameworks.

The four frameworks converge more than they diverge. All require special process validation that is based on risk, traceable and maintained over time. The difference lies in details of form and emphasis - rather than the underlying logic.

---

The common foundation: risk, validation and traceability

ISO 13485:2016 (clause 7.5.6) is the common denominator - the requirement to validate what cannot be verified. ISO 14971 provides the risk logic that determines the level of rigour. Each regulation adds its own layer to this foundation. Those who build from the common core address all four through a single effort; those who start from each regulation in isolation repeat the same work four times - with four opportunities for inconsistency.

FDA QMSR: the era of convergence

The QMSR (Quality Management System Regulation) replaces the former QSR (21 CFR 820) and incorporates ISO 13485:2016 by reference, effective from 2 February 2026. In practice, it brings US requirements closer to the international standard already used by much of the world - reducing, rather than increasing, the distance between systems. For those already operating under ISO 13485, this is convergence; for those who treated the FDA as a separate universe, it is time to read again.

MDR 745/2017: Europe's evidence threshold

The European regulation places strong emphasis on validation evidence, process control and notified body oversight. Sterilisation, controlled environments and sterile barriers fall within its scope, with an expectation of robust traceability - and reading it alongside European Good Manufacturing Practice raises the threshold for documentation and monitoring. The MDR does not ask for a different system; it asks for the same system, with more substantial evidence.

RDC 751/2022: Brazilian requirements follow the same logic

In Brazil, RDC 751/2022 and Good Manufacturing Practice place special process validation within the same framework: risk, validation, control and records. For Brazilian manufacturers that export, the good news is that meeting RDC 751 through a well-structured system already builds much of what the FDA and MDR require - provided the architecture is unified from the outset.

Revalidation and ongoing monitoring: where compliance stays alive

Validation is a milestone. Maintaining validated status is the work. All four frameworks expect a revalidation strategy triggered by change and risk - rather than an arbitrary calendar - and ongoing monitoring that demonstrates continued process capability. Has the supplier, load configuration, packaging material or cleanroom parameter changed? The question is not "When is routine revalidation due?" but "Does this change affect the validation premise?"

The dossier and traceability matrix: the evidence that connects everything

Organised evidence turns a good system into a defensible one. For each special process, the traceability matrix connects risk → specification → testing → acceptance criterion → monitoring. The validation dossier brings this story together so that any auditor - ANVISA, FDA or notified body - can follow any thread and find its next link. One well-constructed dossier addresses all four regulations.

---

The most common strategic mistake

Allowing each market to direct its own validation. The result is a fragmented file in which the FDA version says one thing, the European version another and the ANVISA version a third - and the first inconsistency an auditor finds undermines confidence in everything else. One system, one body of evidence, multiple regulatory interpretations: that is the architecture that survives audits on three continents.

Fragmented compliance gets one audit approved at a time. An integrated system protects the patient in any market - and defends the company in all of them.

Is your validation a single system interpreted through several regulatory frameworks, or four projects that have yet to communicate?

---

At HSC Global, we help medical device manufacturers build a unified special process validation programme - sterilisation, cleanrooms and sterile barriers - with a dossier and traceability matrix that address ISO 13485, FDA QMSR, MDR 745/2017 and RDC 751/2022 simultaneously.

Explore the Special Process Validation for Medical Devices course or speak to our team.

Let us discuss your validation system.

#MedicalDevices #ISO13485 #QMSR #MDR #RDC751 #ProcessValidation #RegulatoryAffairs #QualityManagement #MedicalDevices #ANVISA #FDA #RegulatoryCompliance #HSCGlobal